
Het Financieele Dagblad
BusinessKankermedicijn van NKI afgewezen door Europese toezichthouder
Cancer drug from NKI rejected by European regulator
The Dutch Cancer Institute (NKI) has had a cancer medication rejected by the European regulator. The Institute is turning to foundations to fund proper research.